Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…Abstract Number: 13 • 2016 ACR/ARHP Annual Meeting
Genetic Variants of the Vasoactive Intestinal Peptide (VIP) Gen in Association with Rheumatoid Arthritis Treatment Requirements
Background/Purpose: Biomarkers to recognize patients with a more intensive therapy necessity in rheumatoid arthritis are essential and scarce. VIP has shown immunoregulatory properties both in…Abstract Number: 577 • 2016 ACR/ARHP Annual Meeting
TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells
Background/Purpose: DNA is fragmented and released into blood circulation as a circulating cell-free DNA (ccfDNA) because of damage or death of cells. Although the…Abstract Number: 1106 • 2016 ACR/ARHP Annual Meeting
Test of the Spleen Tyrosine Kinase Inhibitor Fostamatinib in a Translational Joint Tissue Model Show Significant Effect on Bone, but Not on Synovial Tissue
Background/Purpose: The Spleen tyrosine kinase (Syk) inhibitor fostamatinib was not approved as treatment for rheumatoid arthritis (RA) due to insufficient effect on joint structure in…Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting
The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Background/Purpose: Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…Abstract Number: 2823 • 2016 ACR/ARHP Annual Meeting
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Background/Purpose: Proteomic screening is an efficient approach for identifying protein biomarkers in various inflammatory diseases. Our preliminary proteomic analysis revealed elevated levels of urinary angiostatin,…Abstract Number: 3218 • 2016 ACR/ARHP Annual Meeting
Synovial Mast Cells Associate with High Disease Activity and Predict Radiographic Progression at 12 Months in Patients with Early Rheumatoid Arthritis
Background/Purpose: Mast cells (MCs) are immune cells present in the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, although their exact contribution…Abstract Number: 28 • 2016 ACR/ARHP Annual Meeting
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid…Abstract Number: 587 • 2016 ACR/ARHP Annual Meeting
Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis
Background/Purpose: Circulating anti-citrullinated peptide antibodies (ACPA) have been proposed as an important clinical test for stratification of patients presenting with rheumatoid arthritis (RA). ACPA may…Abstract Number: 1201 • 2016 ACR/ARHP Annual Meeting
Deconvolution of Immune Cell Proportions from Whole Blood RNA Using Next-Generation Sequencing
Background/Purpose: Measurements of immune cell proportions from whole blood can be used to detect pharmacodynamic effects, as a marker for prognosis and to aid in…Abstract Number: 1776 • 2016 ACR/ARHP Annual Meeting
Analysis of Progressive Brain and Corpus Callosum Atrophy and Association with Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Background/Purpose: The pathophysiology of brain damage SLE is complex. The aim of this study was to determine brain atrophy progression and the association with Th1…Abstract Number: 2427 • 2016 ACR/ARHP Annual Meeting
Identification of Biomarkers Using Tear Proteomics in Children with Chronic Anterior Uveitis
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) are at risk for anterior uveitis which can lead to ocular complications and vision loss. The ANA is…Abstract Number: 2835 • 2016 ACR/ARHP Annual Meeting
Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Background/Purpose: While autoantibodies production and immune complex deposition are cornered as hallmark features of systemic lupus erythematosus (SLE), there is growing evidence to propose the…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 96
- Next Page »